Vanda Pharmaceuticals, Inc. (VNDA) Posts Q2 Loss of 28c/Share
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.22 +3.78%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
LUNA, BTTX, VAXX, More
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
LUNA, BTTX, VAXX, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q2 EPS of ($0.28), $0.01 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $8.38 million versus the consensus estimate of $8.3 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'
- UP Fintech Holding Limited to Report Second Quarter 2026 Financial Results on August 26, 2026
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
